These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8180292)

  • 1. The interaction of proton pump inhibitors with cytochromes P450.
    Tucker GT
    Aliment Pharmacol Ther; 1994; 8 Suppl 1():33-8. PubMed ID: 8180292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
    Meyer UA
    Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S21-5. PubMed ID: 8930576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
    Li XQ; Andersson TB; Ahlström M; Weidolf L
    Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
    Andersson T
    Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
    Pauli-Magnus C; Rekersbrink S; Klotz U; Fromm MF
    Naunyn Schmiedebergs Arch Pharmacol; 2001 Dec; 364(6):551-7. PubMed ID: 11770010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of pantoprazole on xenobiotic metabolizing enzymes in rat liver microsomes: a comparison with other proton pump inhibitors.
    Masubuchi N; Hakusui H; Okazaki O
    Drug Metab Dispos; 1997 May; 25(5):584-9. PubMed ID: 9152597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of proton pump inhibitors--an overview.
    Arnold R
    Aliment Pharmacol Ther; 1994; 8 Suppl 1():65-70. PubMed ID: 8180297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug interactions with proton pump inhibitors.
    Unge P; Andersson T
    Drug Saf; 1997 Mar; 16(3):171-9. PubMed ID: 9098655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of proton pump inhibitors on thyroid hormone metabolism in rats: a comparison of UDP-glucuronyltransferase induction.
    Masubuchi N; Hakusui H; Okazaki O
    Biochem Pharmacol; 1997 Dec; 54(11):1225-31. PubMed ID: 9416973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of pantoprazole drug interactions in man.
    Steinijans VW; Huber R; Hartmann M; Zech K; Bliesath H; Wurst W; Radtke HW
    Int J Clin Pharmacol Ther; 1994 Aug; 32(8):385-99. PubMed ID: 7981922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.
    Simon WA; Büdingen C; Fahr S; Kinder B; Koske M
    Biochem Pharmacol; 1991 Jul; 42(2):347-55. PubMed ID: 1650212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of the CYP1A induction potential of pantoprazole in primary rat hepatocytes: a comparison with other proton pump inhibitors.
    Masubuchi N; Okazaki O
    Chem Biol Interact; 1997 Nov; 107(1-2):63-74. PubMed ID: 9402950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pantoprazole and cyclosporine or tacrolimus.
    Schwrer H; Lorf T; Ringe B; Ramadori G
    Aliment Pharmacol Ther; 2001 Apr; 15(4):561-2. PubMed ID: 11284790
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.
    Andersson T; Holmberg J; Röhss K; Walan A
    Br J Clin Pharmacol; 1998 Apr; 45(4):369-75. PubMed ID: 9578184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment strategies for gastroesophageal reflux disease.
    Humphries TJ
    Clin Ther; 2000 Dec; 22(12):1590-1. PubMed ID: 11192149
    [No Abstract]   [Full Text] [Related]  

  • 16. Proton pump inhibitors and their drug interactions: an evidence-based approach.
    Gerson LB; Triadafilopoulos G
    Eur J Gastroenterol Hepatol; 2001 May; 13(5):611-6. PubMed ID: 11396546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes.
    Masubuchi N; Li AP; Okazaki O
    Chem Biol Interact; 1998 Jul; 114(1-2):1-13. PubMed ID: 9744552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors.
    Kita T; Sakaeda T; Baba T; Aoyama N; Kakumoto M; Kurimoto Y; Kawahara Y; Okamura N; Kirita S; Kasuga M; Okumura K
    Biol Pharm Bull; 2003 Mar; 26(3):386-90. PubMed ID: 12612455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.
    Kromer W
    Scand J Gastroenterol Suppl; 2001; (234):3-9. PubMed ID: 11768559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline.
    Dilger K; Zheng Z; Klotz U
    Br J Clin Pharmacol; 1999 Sep; 48(3):438-44. PubMed ID: 10510158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.